Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Production / Operations Routine +

Triera Biosciences Completes Innovative Solutions Canada Contract, Advances Platform Toward New Candidate Development

Triera Advances Flu Platform While Nasdaq Compliance Clock Ticks

By The Northwire Desk — AI Analysis Apr 14, 2026 · 08:31 ZEN · 0.73 Zentek Ltd.
Executive Summary
  • Triera Biosciences (Zentek subsidiary) completed an Innovative Solutions Canada (ISC) contract focused on H5N1 avian influenza aptamer development.
  • Executed Ontario Centres of Innovation (OCI) Collaborate 2 Commercialize agreement for seasonal influenza candidates ($300,000 budget).
  • Shift in focus from pandemic risks to common seasonal Influenza A subtypes (H1N1 and H3N2).
  • Technical scope includes multivalent aptamer engineering, dose-finding, pharmacokinetic modeling, and GLP-style toxicology studies.
  • Previous news confirms Triera launched CRO services for custom aptamer discovery in March 2026 to generate near-term revenue.
Material Impact
  • The news represents incremental progress on the Triera pipeline rather than a fundamental valuation shift.
  • Funding amounts ($300,000 OCI match) are small relative to company operating costs and do not materially extend cash runway compared to October 2025 financing.
  • Operational milestones (GLP studies, seasonal flu focus) validate the technology but do not resolve immediate liquidity or Nasdaq compliance risks.
  • Consistent with historical progression of Triera updates (Sept 2025 H1N1 results, March 2026 CRO launch), indicating expected execution rather than surprise upside.
  • Albany Graphite PEA engagement announced April 9 is a positive catalyst but scheduled for summer completion, limiting immediate price impact.
ZEN · Price
Company Overview
  • Zentek Ltd. operates three core platforms: Albany Graphite Corp., ZenGUARD™ (air filtration), and Triera Biosciences (aptamer diagnostics/therapeutics).
  • Albany Graphite Project: Focus on ultra-high-purity graphite for nuclear, battery, and defense supply chains; confirmed 5N purity (99.9992%) with low boron content suitable for nuclear applications.
  • ZenGUARD™: Enhanced air filtration media targeting infectious aerosol removal; facing regulatory classification challenges in Canada but pursuing US partnerships.
  • Triera Biosciences: Aptamer-based platform licensed from McMaster University; generating revenue via CRO services and government contracts (ISC).
Read the original news release →

More from Zentek Ltd.

Jul 07, 2026 · 09:19

Zentek secures its first US commercial order, validating its pilot program while facing a Nasdaq delisting deadline at $0.67.

M&A / Property Jun 29, 2026 · 08:01

Zentek secures U.S. licensing for its ZenGUARD filtration media as the Albany project preliminary economic assessment nears completion.

M&A / Property Jun 26, 2026 · 09:28

Zentek Forms U.S. Joint Venture to Position Its Albany Ultra-High-Purity Graphite in the North American National-Security Supply Chain

M&A / Property Jun 09, 2026 · 11:12

Zentek secured a U.S. patent for its ZenGUARD graphene technology, though commercial execution and Nasdaq compliance remain critical challenges for the company.

Other May 27, 2026 · 09:10

Zentek closes $18M oversubscribed financing to advance Albany graphite PEA, but stock drifts below issue price amid Nasdaq compliance pressure.

Financings May 19, 2026 · 07:31

Zentek Secures Liquidity with Oversubscribed Offering Amid Nasdaq Compliance Pressure

Financings